Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 9/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 3/20 | 0.41 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP7 | P09237 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653521 | 0.89 | SLC6A7 (0.47) | SMOSLC6A7CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL5653029 | 0.88 | HSD11B1 (0.46) | SMOSLC6A7CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL14366931 | 0.88 | MMP8 (0.52) | SMOSLC6A7CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL14414563 | 0.87 | SMO (0.42) | SMOSLC6A7CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL5653667 | 0.85 | GRM5 (0.46) | SMOSLC6A7CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL5652538 | 0.83 | SMO (0.45) | SMOSLC6A7CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL5654349 | 0.83 | SMO (0.53) | SMOSLC6A7CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL5652388 | 0.83 | SMO (0.50) | SMOSLC6A7CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL5652959 | 0.83 | GSK3B (0.51) | SMOSLC6A7CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL5654070 | 0.81 | GRM5 (0.45) | SMOALDH1A1MMP3MMP8MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | TRIMERIS, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259879-A1 | Piperazine and piperidine biaryl derivatives | CYP3A5, CYP3A43, CCR5 | SMO 3378/4885SLC6A7 53/4885CYP2C19 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.